195940.KQ
195940.KQ
KR7195940002
HK inno.N
Loading chart...

Company Profile

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. The company has joint research and development agreement with Nextgen Bioscience for NXC680, a candidate compound for treatment of Idiopathic Pulmonary Fibrosis. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.

Related stocks

006280.KS
006280.KS • South Korea
GC Biopharma Corp.
129,400 KRW
1.1B USD 1Y -2.2%
185750.KS
185750.KS • South Korea
CHONGKUNDANG
65,900 KRW
647.98M USD 1Y -19.9%
003850.KS
003850.KS • South Korea
Boryung
8,610 KRW
525.24M USD 1Y +0.2%
068760.KQ
068760.KQ • South Korea
Celltrionph
38,800 KRW
1.28B USD 1Y -27.1%
069620.KS
069620.KS • South Korea
DAEWOONG PHARM
108,500 KRW
931.65M USD 1Y -18.3%
009420.KS
009420.KS • South Korea
HANALL BIOPHARMA
44,000 KRW
1.67B USD 1Y +26.4%
2005.HK
2005.HK • Hong Kong SAR China
SSY GROUP
2.67 HKD
975.57M USD 1Y -10.6%
300267.SZ
300267.SZ • China
ER-KANG
3.36 CNY
1.04B USD 1Y -1.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
43.2% p.a.
Max Drawdown (5Y)
-57.3%
Sharpe Ratio (5Y)
-0.28
Beta Factor
0.56
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (43.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -57.3% in the extended horizon.
ende